{"id":"W2597559961","doi":"10.1200/jco.2013.31.15_suppl.tps652","title":"A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(–) breast cancer who have not received any prior systemic anticancer treatment for advanced disease.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Palbociclib; Medicine; Letrozole; Internal medicine; Adverse effect; Oncology; Regimen; Progression-free survival; Neutropenia; Placebo; Clinical endpoint; Fulvestrant; Breast cancer; Phases of clinical research; Metastatic breast cancer; Clinical trial; Cancer; Tamoxifen; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00156237,0.0006479161,0.005289396,0.0002148005,0.0001734538,0.00003028527,0.0003519492,0.0002687221,0.0001029422],"category_scores_gemma":[0.0003273056,0.0003532574,0.0007465121,0.0001899483,0.0007937988,0.0004538206,0.00004203994,0.0003693734,0.000001294999],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003135821,"about_ca_system_score_gemma":0.003164094,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008043702,"about_ca_topic_score_gemma":0.0008696567,"domain_scores_codex":[0.9935185,0.0007002747,0.00363168,0.0006451411,0.0007165972,0.0007877466],"domain_scores_gemma":[0.9869202,0.005527679,0.004279453,0.0006606944,0.001775285,0.0008366449],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8308017,0.01592929,0.001533341,0.0001545668,0.006564812,0.00005503444,0.003798546,0.001916884,0.0008683114,0.000007150544,0.00002330311,0.1383471],"study_design_scores_gemma":[0.8426484,0.135306,0.004013411,0.0004483001,0.004493584,0.00006590013,0.007481027,0.002826329,0.000521268,0.00001091257,0.001896631,0.00028824],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9777557,0.00284684,0.0006212119,0.002408308,0.001250819,0.01479261,0.0002880352,0.00002281588,0.00001362202],"genre_scores_gemma":[0.9890798,0.002501061,0.001465209,0.0002650244,0.001337629,0.004925261,0.0000193064,0.0001062505,0.0003004022],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1380589,"threshold_uncertainty_score":0.9998919,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1124280186970736,"score_gpt":0.4640249376706437,"score_spread":0.3515969189735701,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}